Ralph Smalling, who serves as Head of Regulatory at GENELUX Corp (NASDAQ: GNLX), sold a total of 585 shares of common stock in two separate trades executed on March 24 and March 25, 2026. The sales were recorded on a Form 4 filing with the Securities and Exchange Commission and include a footnote stating the shares were disposed of to cover estimated taxes related to the vesting of restricted stock units.
On March 24, Smalling sold 345 shares at $2.42 per share. The following day, March 25, he sold an additional 240 shares at $2.51 per share. Proceeds from the combined transactions totaled $1,437.
Following these transactions, Smalling is reported to directly own 68,073 shares of Genelux common stock. The company’s shares are trading at $2.63 and are down 39% year-to-date, according to InvestingPro data cited in the disclosure. Genelux carries a market capitalization of $117.59 million, while analyst price targets in the market range from $10 to $31 per share.
Separately, Genelux announced that it has priced an underwritten public offering of 6.67 million shares at $3.00 per share, an effort intended to raise approximately $20 million before expenses. The offering agreement also includes a 30-day option allowing the underwriter to purchase up to an additional 1 million shares. Lucid Capital Markets is listed as the sole book-running manager for the offering. The initial announcement of the proposed public offering coincided with a 10.3% decline in after-hours trading.
On the clinical front, H.C. Wainwright has maintained a Buy rating on Genelux, citing favorable trial outcomes. The firm highlighted data showing that Olvi-Vec, when combined with platinum chemotherapy, produced a 33% objective response rate in patients with small cell lung cancer. In leadership changes, Genelux appointed Dr. Jason Litten as Chief Medical Officer effective early January 2026; Dr. Litten will oversee clinical development and strategy for ongoing cancer trials.
The Form 4 filing that reported Smalling’s sales included the tax-related footnote explaining the rationale for the disposals. Additional subscription-content notes indicate InvestingPro subscribers have access to 11 additional tips on GNLX, which include insights into the company’s cash position and financial health.
The transactions by the regulatory chief, the newly priced offering, recent analyst commentary, and the appointment of a new CMO together frame the current public developments at Genelux. Each of these items is documented in company filings and analyst disclosures referenced in public filings and subscription data cited in the company reporting.